Skip to main content

Table 4 The heterogeneity of meta-analysis after the following studies were removed

From: PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis

Study

I2 (%)

Pheterogeneity

HR (95%)

Kojima 2020, KEYNOTE-181

0.0

0.923

0.72 (0.64, 0.81)

Kato 2019, ATTRACTION-3

0.0

0.882

0.72 (0.65, 0.81)

Huang 2020, ESCORT

0.0

0.856

0.74 (0.66, 0.83)

Xu 2020, ORIENT-2

0.0

0.848

0.74 (0.66, 0.82)

Ajani 2021, RATIONALE 302

0.0

0.895

0.75 (0.66, 0.84)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us